Oncology Biologics Development Primer

Susan Jerian, MD
OncoRD, Inc.

Carl H. June, MD
University of Pennsylvania

Mercedes Serabian, MS, DABT
Food and Drug Administration , CBER

Robert J. Zimmerman, SD
Zimmerman Consulting

Sunil Chada, PhD
Introgen Therapeutics, Inc.

Robert Charnas, PhD
Amgen, Inc.

Matt Coffey, PhD
Oncolytics Biotech Inc.

Laurence Elias, MD
Geron Corporation

Marta Fields
Amgen, Inc.

Lothar H. Finke, MD
ARGOS Therapeutics

Ying Huang, PhD
Food and Drug Administration, CBER

Rachel W. Humphrey, MD
Bristol-Myers Squibb Company

Elizabeth M. Jaffee, MD
Johns Hopkins University

Susan Jerian, MD
OncoRD, Inc.

Carl H. June, MD
University of Pennsylvania

Patrica Keegan, MD
Food and Drug Administration

Samir Khleif, MD
National Cancer Institute, CCR

John M. Kirkwood, MD
University of Pittsburgh

Frederic Lehmann, MD
GlaxoSmithKline Biologicals s.a.

Michael T. Lotze, MD
University of Pittsburgh Cancer Institute

Crystal Mackall, MD
National Cancer Institute, Pediatric Oncology

Andrew J. McDougal, PhD, DABT
Food and Drug Administration, CDER

Jeffrey Miller, MD
University of Minnesota

C. Randal Mills, PhD
Osiris Therapeutics, Inc.

Christopher Moulding
USC Stevens Institute for Innovation

David Parkinson, MD
Nodality, Inc.

Raj Puri, MD, PhD
Food and Drug Administration, CBER

Nicholas P. Restifo, MD
National Cancer Institute

Michel Sadelain, MD, PhD
Memorial Sloan-Kettering Cancer Center

Mercedes Serabian, MS, DABT
Food and Drug Administration, CBER

Ken Takeshita, MD
Celgene

Robert H. Vonderheide, MD, D.Phil
University of Pennsylvania, Abramson Family Cancer Rsch. Inst.

Anthony R. Welch, PhD
National Cancer Institute

Robert J. Zimmerman, SD
Zimmerman Consulting